Peptides for Tendon and Ligament Injuries: What Is Used and Why

Muscle bleeds when you tear it, and that blood brings everything repair requires. Tendon does not. This is the whole reason the category exists.

A tendon is mostly type I collagen in parallel bundles with a small population of tenocytes between the fibers: few cells, far from any capillary, producing collagen that takes months to be laid down and realigned. A ligament is built the same way but runs bone to bone, and its job is restraint, which is why a ligament that repairs long and loose is a functional failure even when structurally intact.

The second thing worth knowing is that chronic tendon pain is usually not inflammation. What imaging and biopsy describe in long-standing cases is a degenerative picture: disorganized collagen, increased ground substance, and abnormal new vessel and nerve ingrowth. That is why the word most clinicians now use is tendinopathy rather than tendinitis, and why anti-inflammatory strategies often disappoint after the first few weeks. It also decides which peptide has the clearer rationale: KPV early, when a tendon is genuinely reactive; the vessel, migration and matrix peptides in a long-standing degenerative tendon where repair never got going.

The table is a map of the rationale, not a claim of proof. Each row is a pathway a peptide has been reported to act on in animal or cell work; whether that translates into a faster or stronger human tendon has not been tested in a trial. Underneath most of it is a load problem, and any plan that does not change the load is treating the symptom.

A 15-amino-acid fragment of a protein found in human gastric juice. Animal research describes it promoting new blood-vessel formation through the VEGF receptor pathway and the nitric-oxide system, and upregulating growth-hormone receptor expression in tendon fibroblasts, which makes those cells more responsive to signals already circulating. Both of those map directly onto what a tendon lacks. The published tendon work is in rats, not people.

It is the most tendon-specific literature of any peptide on this page, and it is all in rats and rat cells. A 2003 paper in the Journal of Orthopaedic Research reported faster healing of a transected rat Achilles tendon; a 2006 paper in the same journal reported improved reattachment after Achilles detachment from bone; and a 2010 paper, again in the Journal of Orthopaedic Research, transected the medial collateral ligament of the rat knee and reported improved ligament healing over ninety days whether the peptide was injected, given in drinking water, or applied as a cream. The studies measure things a rat cannot fake: time to weight-bearing, tensile strength, collagen histology. At the cell level, a 2011 paper in the Journal of Applied Physiology reported increased survival, migration and outgrowth of cultured tendon fibroblasts, and a 2014 paper in Molecules reported increased growth hormone receptor expression in the same cells; a 2021 paper in Biomedicines extended the animal work to the myotendinous junction, and a 2026 review in Pharmaceuticals summarizes it. The FDA's own July 2026 briefing document puts it the same way: pharmacological studies have suggested BPC-157 "promotes healing of transected tendons in rodents." That is the ceiling of the evidence. BPC-157 suits the patient whose tendon or ligament has stalled, who has a loading program in place, and who wants the simplest single-molecule option first. Its reference is at what is BPC-157.

Related to thymosin beta-4. It binds actin, the protein that gives a cell its structure and lets it move, which is the basis of its described effect on repair cells migrating into damaged tissue. Published work also reports new vessel formation, downregulation of inflammatory mediators, and reduced scar formation in some injury models. BPC-157 vs TB-500 compares the two directly, and what is BPC-157 + TB-500 covers the combination.

Thymosin beta-4 has a deeper general literature than BPC-157 but a thinner tendon one: directional migration of human endothelial cells in FASEB Journal in 1997, accelerated wound closure in rats in the Journal of Investigative Dermatology in 1999, and increased matrix metalloproteinase expression during repair in the Journal of Cellular Physiology in 2006. On the human side, a 2010 randomized placebo-controlled study in the Annals of the New York Academy of Sciences reported intravenous thymosin beta-4 was well tolerated in healthy volunteers, and a 2015 phase 2 trial in Cornea reported improvement in severe dry eye. The one study that tests TB-500 by name in a tendon is the 2026 rat paper below. TB-500 suits the patient whose picture is poor-quality repair tissue and scarring, and it is usually prescribed with BPC-157 rather than instead of it. Its reference is at what is TB-500.

The BPC-157 + TB-500 stack exists because the two are described as acting on different limitations of the same tissue: BPC-157 on blood supply and the responsiveness of tendon cells, TB-500 on whether repair cells can reach and move through the injury. One vial means one injection and one set of pharmacy directions. What the combination does not have is evidence that it outperforms either peptide alone; the 2026 rat study reported no additional benefit from the pair. Pricing is at /cost/bpc-tb-stack.

A copper-binding tripeptide that delivers copper to the enzymes that depend on it. Research describes increased synthesis of collagen, elastin and proteoglycans, and modulation of the balance between matrix metalloproteinases and their inhibitors. Since a degenerative tendon is a matrix problem, this is the component aimed at the tissue quality rather than at the symptoms.

GHK-Cu has the oldest literature of the four: stimulated collagen synthesis in cultured fibroblasts in FEBS Letters in 1988, increased connective tissue accumulation in rat wounds in the Journal of Clinical Investigation in 1993, and a 1994 paper in Wound Repair and Regeneration reporting enhanced closure of diabetic ulcers with a topical copper-peptide preparation, which is human data, though for skin and by a different route. None of it is tendon-specific; the rationale is that a tendon is made of the collagen the peptide is described as acting on in skin, and it is untested in a tendon trial. GHK-Cu suits the patient whose imaging or history points to poor tissue quality: a thickened, disorganized tendon on ultrasound, a ligament that repaired lax, or someone in their fifties or sixties for whom collagen turnover is the limiting factor. It is why GLOW and KLOW add it to the base pair. Its reference is at what is GHK-Cu.

The last three amino acids of alpha-MSH, described as interfering with NF-kB and MAPK signalling and reducing cytokines such as TNF-alpha and IL-6. It earns a place when inflammation is genuinely part of the picture, which is more often true early than late.

KPV's research base is inflammatory bowel and skin, not tendon: a 2008 paper in Gastroenterology reported reduced intestinal inflammation in mice, and a 2008 paper in Inflammatory Bowel Diseases reported anti-inflammatory effects in murine colitis. There is no KPV tendon study. KPV suits the reactive tendon in its early weeks, the sprain that is still hot and swollen, or the chronic tendon that has flared, and it is why KLOW exists as a separate product from GLOW. Its reference is at what is KPV.

KLOW combines GHK-Cu, KPV, BPC-157 and TB-500 in one vial, covering all five stages in the table above; it is the blend for a long-standing injury that is still reactive. GLOW is the same without KPV, for the injury where inflammation has settled and tissue quality is the concern. REVIVE pairs GHK-Cu and a smaller amount of TB-500 with the growth-hormone secretagogues CJC-1295 and ipamorelin, for general recovery in someone who also has a slow injury. Which blend, if any, is a physician's decision; /cost/klow, /cost/glow and /cost/revive-blend carry current pricing.

A 2026 paper in Joint Diseases and Related Surgery is the first to test BPC-157 and TB-500 by name, alone and together, in a tendon model. Thirty-two rats had the Achilles tendon cut and repaired and were assigned to control, BPC-157, TB-500 or both, treated daily for four weeks. Maximum load to failure was higher in both peptide groups than in controls, reaching statistical significance for TB-500; TB-500 also produced significantly better tendon architecture scores, while BPC-157 alone showed numerically better scores that did not reach significance. The combination did not do better than either peptide by itself. The paper calls itself exploratory. Two things follow: TB-500 now has a tendon study of its own rather than an inference from skin and heart, and the "stack" has its first data point suggesting the pair is not additive in a rat at four weeks.

The peptides are added to a treatment that has human trial evidence. A 2015 randomized controlled trial in the American Journal of Sports Medicine reported that both heavy slow resistance and eccentric training improved Achilles tendinopathy. A 2009 randomized trial in the Scandinavian Journal of Medicine and Science in Sports reported that a corticosteroid injection worked fastest in patellar tendinopathy but the loading programs held up at follow-up when the injection did not, and a 2010 systematic review in The Lancet reported the same pattern across tendinopathy trials. No peptide has been tested against those standards.

There is no randomised human trial showing that any of these improves tendon healing. Animal work on BPC-157 describes a wide margin between effective and problematic doses, and reported tolerability is good, which is a different statement from proven efficacy. Neither GHK-Cu nor KPV has a tendon or ligament study in any species; their place in the blends rests on mechanism. Two 2026 reviews in the American Journal of Sports Medicine describe the musculoskeletal evidence for BPC-157 and TB-500 as animal-based and call for human trials. The FDA's July 2026 briefing document noted that BPC-157 had been nominated for tendonitis but that the agency did not evaluate that use, because the nomination lacked sufficient information and it "did not identify clinical studies using BPC-157 in these populations."

• An effect size in humans. Nobody can tell you how much faster or stronger a given tendon will recover, because that trial has not been run.
• A human timeline. The weeks quoted by prescribers are clinical experience, not trial endpoints.
• Superiority of the combination. The one rat study that tested it reported no additive benefit.
• Long-term safety over years of continuous use in humans.
• Any efficacy as an FDA-approved treatment. None of these is approved for anything.

None of these are FDA approved. They are compounded at a US FDA-registered pharmacy against a valid prescription. A provider offering you a healing timeline for a tendon is making it up. The broader repair picture is in peptides for healing and the joint-specific version in peptides for joint health.

In 2023 the FDA placed BPC-157, TB-500 and KPV, with other peptides, in Category 2 of its interim 503A bulk drug substances list, the category for nominated substances the agency said raised significant safety concerns. On 15 April 2026 the FDA announced it was removing twelve peptides from Category 2, including BPC-157, TB-500 and KPV, effective seven days later. The FDA's Category 2 page, current as of 22 April 2026, now shows BPC-157, TB-500 (thymosin beta-4 fragment), KPV and GHK-Cu under "nominated but withdrawn." Removal does not by itself establish that a substance meets the criteria for compounding; it removes the flag.

On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV and TB-500 and voted 8 to 6, with one abstention, to recommend adding each of them to the 503A Bulks List. The committee recommended six of the seven peptides on its agenda. The votes went against the FDA's own staff position: the agency's briefing document had proposed that BPC-157, KPV and TB-500 each not be included, citing incomplete characterization and the absence of adequate clinical data. A committee vote is a recommendation; the FDA issues its own determination afterwards, and formal addition requires rulemaking. As of September 2026 that determination is pending.

Injectable GHK-Cu was one of the twelve peptides removed from Category 2 in April 2026. Non-injectable GHK-Cu sits in Category 1, the list of substances under evaluation: the FDA's 503A list updated 14 May 2026 carries "GHK-Cu (except for injectable routes of administration)" there, after a nominator withdrew and then partly reinstated its nomination in April and May, and states that the agency intends to consult the advisory committee about GHK-Cu before the end of February 2027. GHK-Cu was not on the July 2026 agenda.

All four peptides remain legal to prescribe and dispense under a valid prescription from a physician licensed in your state, compounded by a state-licensed pharmacy. None is FDA approved, none becomes approved by being added to a bulks list, and the position can change again; this page is dated September 2026.

The World Anti-Doping Agency's 2026 Prohibited List, in force from 1 January 2026, names BPC-157 under S0, non-approved substances, prohibited at all times in and out of competition. TB-500 is named under S2.3 as "Thymosin-β4 and its derivatives e.g. TB-500," a class that also covers any growth factor modulator "affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching," likewise prohibited at all times. GHK-Cu and KPV are not named, but S0 is a catch-all for any substance without regulatory approval for human use, so a tested athlete should treat both as questions for their anti-doping organization. See peptides for athletes.

Lateral elbow pain can be a nerve entrapment. Posterior heel pain can be a bursa or a bone stress reaction. Groin "tendinopathy" is regularly a hip joint. The rationale above only applies if the tissue is a tendon or ligament, so the physician wants to know where it hurts, what provokes it, and whether anyone has imaged it.

A full-thickness rupture, a ligament that has lost its integrity, an avulsion where the tendon has pulled a fragment of bone away: these are surgical questions, so the physician asks about a snap, a pop, a sudden loss of strength or a joint that gave way before anything else.

Night pain, pain unrelated to activity, fever, unexplained weight loss, or a hot swollen joint with no injury to explain it need a medical assessment first. So does a tendon problem in someone recently prescribed a fluoroquinolone antibiotic, a class with a documented association with tendon rupture. The physician also asks what changed in the weeks before the pain started, because if that load is still being applied the peptide question is premature, and goes through cancer history, anticoagulants, pregnancy, copper metabolism and competition drug testing.